A5069934601- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Cancer, Hypoxia, and Metabolism
- Artificial Intelligence in Healthcare and Education
- Global Cancer Incidence and Screening
- Bone health and treatments
- CAR-T cell therapy research
- Hormonal and reproductive studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Cancer Risks and Factors
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Radiotherapy Techniques
Huntsman Cancer Institute
2023-2025
University of Utah
2023-2025
Importance The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current approaches attrition rates patients with aUC. Objectives To delineate evolving patterns in aUC using a US-based patient-level sample. Design, Setting, Participants This retrospective cohort study used data from nationwide deidentified electronic health...
The treatment landscape of metastatic prostate cancer (mPCa) is rapidly evolving with the recent approvals poly-ADP ribose polymerase inhibitors (PARPis) as monotherapy or part combination therapy androgen receptor pathway in patients castration-resistant (mCRPC). Already therapeutic armamentarium different types advanced cancers, these molecules have shaped a new era mPCa by targeting genomic pathways altered patients, leading to promising responses. These agents act inhibiting (PARP)...
Importance Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). Objective To assess trends disparities in next-generation sequencing (NGS) testing among mPC aUC. Design, Setting, Participants This retrospective cohort study used an electronic health record–derived database to extract deidentified data of receiving care from US physician practices,...
95 Background: Most pts with prostate cancer bone metastasis experience symptomatic skeletal events (SSEs) [PMID: 23884473], leading to increased morbidity and mortality. BMAs have been approved since 2007 are recommended in mCRPC prevent SSEs metastases or a high risk of osteoporotic fracture. Herein, we sought assess the real-world trends BMA administration mCRPC. Methods: We used de-identified nationwide Flatiron Health electronic health record (EHR)-derived database extract pt-level...
204 Background: In mHSPC, no baseline biomarker reliably predicts progression-free survival (PFS). Identifying pts unlikely to benefit from current therapies could enable personalized management and better pt selection for clinical trials. Herein, we investigate the capacity of a novel AI-based digital pathology platform prognosticate in mHSPC. Methods: Pts diagnosed with mHSPC available slides undergoing systemic therapy at Huntsman Cancer Institute, University Utah were eligible. Whole...
205 Background: Up to 30% of pts with advanced prostate cancer have HRRalt [PMID: 32343890]. The presence tumor has been associated poor prognosis in the metastatic castration-resistant setting 38417742]. However, impact patients mHSPC is unknown. Herein, we sought interrogate effect on survival outcomes mHSPC. Methods: This IRB-approved retrospective study used nationwide (US-based) de-identified Flatiron Health-Foundation Medicine clinico-genomic database (FH-FMI CGDB). data originated...
108 Background: PARPi are approved for the treatment of pts with mCRPC either as single agents or a combination an androgen receptor pathway inhibitor (ARPI) [PMID: 37442702]. In US Food and Drug Administration (FDA) pooled analysis, benefit from appeared greatest harboring BRCA1/2 alterations 38484203]. However, real-world uptake in is unknown. Herein, our objective was to assess usage alterations. Methods: A de-identified nationwide Flatiron Health electronic health record (EHR)-derived...
162 Background: Pts with mCRPC after progression on docetaxel and androgen receptor pathway inhibitors (ARPIs), have limited treatment options. Even the changing landscape, cabazitaxel remains an effective approved therapy in this setting for these pts. However, real-world data efficacy trends of usage remain limited. Herein, we aimed to assess survival outcomes patterns pts receiving single-agent a setting. Methods: This retrospective study utilized nationwide Flatiron Health electronic...
82 Background: Lu is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical that delivers beta radiation to PSMA-positive cells. It approved for pts with mCRPC who had prior progression on an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy. However, there are limited real-world data the efficacy of based line therapy. Herein, we aimed assess survival outcomes receiving in setting. Methods: This retrospective study utilized nationwide Flatiron Health...
727 Background: Despite the availability of targeted therapies like erdafitinib for pts with aUC susceptible genomic alterations, rate NGS testing remains low at 32% in United States (Hage Chehade...Swami, JAMA Network Open, 2024). Furthermore, limited data exist regarding timing relation to time death. Herein, we sought assess rates end life a real-world patient population. Methods: A de-identified nationwide Flatiron Health electronic health record (EHR)-derived database was used extract...
90 Background: Poly(ADP) ribose polymerase inhibitors and pembrolizumab are approved for patients with metastatic prostate cancer (mPC) susceptible genomic alterations based on NGS testing. We recently reported that the rate of testing in mPC remains low at 29.3% United States (1). Herein, we investigated rates end life a real-world patient population. Methods: This study utilized nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Eligibility: diagnosis...
109 Background: C and Lu are associated with overall survival benefit approved for pts mCRPC after prior treatment docetaxel an androgen receptor pathway inhibitor (ARPI). However, in real-world settings, administering requires coordination across specialties resources [PMID: 36637862], which could delay its administration. Herein, we sought to compare the time from medication order first dose of versus Lu. Methods: This study used pt level data nationwide Flatiron Health electronic health...
173 Background: It is well-established that pts with de-novo mHSPC have poorer survival compared to those metachronous disease. However, the impact of timing metastatic recurrence after definitive therapy on has not been extensively evaluated in mHSPC. Therefore, we assessed prognostic value TTM using SWOG 1216 trial data which randomized androgen deprivation (ADT) orteronel (ORT) or bicalutamide (bic) (NCT01809691). Methods: Eligibility: Only who underwent prostatectomy were included...
75 Background: The Rx landscape of pts with mCRPC has recently evolved the approval lutetium-177-PSMA-617 (Lu-177) and poly(ADP) ribose polymerase inhibitors (PARPi) either as single agents or combinations an androgen receptor pathway inhibitor (ARPI) [PMID: 37442702]. However, real-world data on uptake these are lacking. Herein, we sought to assess patterns attrition rates in era newly approved therapies. Methods: de-identified nationwide Flatiron Health Electronic-Health Record...
42 Background: Artificial intelligence (AI) has transformed many aspects of healthcare, particularly in medical imaging analysis. In mPC, accurate identification bone metastases is crucial guiding pt management. This proof-of-concept study explores the application ChatGPT-4o, a multimodal, generative pre-trained transformer (large language model) with emerging image recognition capabilities, diagnosing from scans and determining disease volume pts mPC. Methods: this IRB-approved,...
100 Background: Metachronous mHSPC is associated with improved outcomes compared to synchronous (de novo) mHSPC. However, there are limited data on the effect of TTM after radical prostatectomy in patients metachronous treated systemic therapies. Our objective was explore association survival a real-world population. Methods: In this IRB-approved retrospective study, eligibility criteria were: pts who underwent and were ADT plus androgen receptor pathway inhibitor (ARPI). disease defined as...
104 Background: Androgen deprivation therapy (ADT) intensification [ADT + androgen receptor-pathway inhibitor (ARPIs) +/- docetaxel] has been shown to improve survival outcomes in pts with mHSPC and is recommended as standard of care by all major guidelines. However, prior studies have underutilization ADT [PMID: 39191549]. There are limited updated large-scale on the use intensification, beyond January 2023. In this study, we aimed assess treatment patterns real-world US, including data...
Importance The treatment landscape of metastatic clear cell renal carcinoma (ccRCC) has rapidly evolved with the approval multiple immune checkpoint inhibitor (ICI)-based combinations. However, clinical data on changes in patterns and attrition before after ICI-based combinations are lacking. Objective To assess rates patients ccRCC Design, Setting, Participants This cohort study used patient-level from a nationwide deidentified electronic health record-derived database, originating around...
Importance The presence of bone pain is significantly associated with worse overall survival (OS) in patients castration-resistant prostate cancer. However, there are few data regarding and outcomes the context metastatic, hormone-sensitive cancer (MHSPC). Objective To compare among MHSPC by or absence baseline at diagnosis. Design, Setting, Participants This post hoc secondary analysis, conducted from September 1 to December 31, 2023, used patient-level SWOG-1216, a phase 3, prospective...